
Viking Therapeutics, Inc.: shareholders and insiders
Price
$24.77
November 20, 2026Market cap $3.2B
What Ploutos Investor adds for Viking Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Aug 7, 2026, from their own Form 4 filings.
Bought on the market
$149.9K
1 person
Sold on the market
$18M
4 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $149.9K by 1 person·sold $18M by 4 people
- 2025: no buys, no sales
- 2026: bought $149.9K by 1 person, sold $18M by 4 people
- Aug 1, 2026Dorothy Elizabeth Kelly-GemmellDirectorKind
- Jul 29, 2026Brian LianPresident & CEOKind
- Jul 29, 2026Greg ZanteChief Financial OfficerKind
- Jul 29, 2026Marianna ManciniChief Operating OfficerKind
- Jul 28, 2026Brian LianPresident & CEOKind
- Jul 28, 2026Greg ZanteChief Financial OfficerKind
- Jul 28, 2026Marianna ManciniChief Operating OfficerKind
- Mar 10, 2026Neil William AubuchonChief Commercial OfficerKind
- Jan 5, 2026Brian LianPresident & CEOKind
- Jan 5, 2026Brian LianPresident & CEOKind
- Jan 5, 2026Brian LianPresident & CEOKind
- Jan 5, 2026Brian LianPresident & CEOKind
- Jan 5, 2026Marianna ManciniChief Operating OfficerKind
- Jan 5, 2026Marianna ManciniChief Operating OfficerKind
- Jan 5, 2026Marianna ManciniChief Operating OfficerKind
- Jan 5, 2026Marianna ManciniChief Operating OfficerKind
- Jan 5, 2026Greg ZanteChief Financial OfficerKind
- Jan 5, 2026Greg ZanteChief Financial OfficerKind
- Jan 5, 2026Greg ZanteChief Financial OfficerKind
- Jan 5, 2026Greg ZanteChief Financial OfficerKind
- Jan 2, 2026Matthew W FoehrKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 1, 2026 | Dorothy Elizabeth Kelly-GemmellDirector | 6,333 | – | – | Form 4 | |
| Jul 29, 2026 | Brian LianPresident & CEO | 148.5K | $33.32 | $4.9M | Form 4 | |
| Jul 29, 2026 | Greg ZanteChief Financial Officer | 21.2K | $33.47 | $710.1K | Form 4 | |
| Jul 29, 2026 | Marianna ManciniChief Operating Officer | 18.2K | $33.47 | $609.6K | Form 4 | |
| Jul 28, 2026 | Brian LianPresident & CEO | 221.7K | – | – | Form 4 | |
| Jul 28, 2026 | Greg ZanteChief Financial Officer | 31.7K | – | – | Form 4 | |
| Jul 28, 2026 | Marianna ManciniChief Operating Officer | 31.7K | – | – | Form 4 | |
| Mar 10, 2026 | Neil William AubuchonChief Commercial Officer | 4,475 | $33.50 | $149.9K | Form 4 | |
| Jan 5, 2026 | Brian LianPresident & CEO | 132.5K | $32.29 | $4.3M | Form 4 | |
| Jan 5, 2026 | Brian LianPresident & CEO | 41.3K | $34.22 | $1.4M | Form 4 | |
| Jan 5, 2026 | Brian LianPresident & CEO | 53.3K | $33.38 | $1.8M | Form 4 | |
| Jan 5, 2026 | Brian LianPresident & CEO | 6,400 | $35.07 | $224.4K | Form 4 | |
| Jan 5, 2026 | Marianna ManciniChief Operating Officer | 1,600 | $35.07 | $56.1K | Form 4 | |
| Jan 5, 2026 | Marianna ManciniChief Operating Officer | 10.5K | $34.22 | $359.3K | Form 4 | |
| Jan 5, 2026 | Marianna ManciniChief Operating Officer | 13.6K | $33.37 | $453.8K | Form 4 | |
| Jan 5, 2026 | Marianna ManciniChief Operating Officer | 32.0K | $32.29 | $1.0M | Form 4 | |
| Jan 5, 2026 | Greg ZanteChief Financial Officer | 1,500 | $32.09 | $48.1K | Form 4 | |
| Jan 5, 2026 | Greg ZanteChief Financial Officer | 10.3K | $34.24 | $352.7K | Form 4 | |
| Jan 5, 2026 | Greg ZanteChief Financial Officer | 13.9K | $33.38 | $464.0K | Form 4 | |
| Jan 5, 2026 | Greg ZanteChief Financial Officer | 32.0K | $32.30 | $1.0M | Form 4 | |
| Jan 2, 2026 | Matthew W Foehr | 16.0K | $35.11 | $561.8K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by VKTX's officers and directors from 2015 up to November 21, 2025, 11 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 6 more, back to 2015
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+95%
- D.E. ShawIn the quarter-49%
- Bridgewater (Dalio)In the quarter-5.3%
- Point72 (Cohen)In the quarter-67%
- Millennium Mgmt (Englander)In the quarter-27%
- AQR CapitalIn the quarter+553%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 1.86M | +95% | $61M | 0.03% |
| D.E. Shaw | 820.1K | -49% | $27M | 0.02% |
| Bridgewater (Dalio) | 83.2K | -5.3% | $2.7M | 0.01% |
| Point72 (Cohen) | 155.2K | -67% | $5.1M | 0.01% |
| Millennium Mgmt (Englander) | 362.0K | -27% | $12M | 0.01% |
| AQR Capital | 1.31M | +553% | $42M | 0.01% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 20.0% of its shares outstanding were held short, -1.5% since the report before.
- Shares held short
- 25.54M
- 20.0%
- Since the report before25.92M on Sep 30, 2026
- -1.5%
- 4.4
- 5.83M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 53%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 16.42M
- Nov 15, 2023: Shares held short 16.97M
- Nov 30, 2023: Shares held short 15.42M
- Dec 15, 2023: Shares held short 14.60M
- Dec 29, 2023: Shares held short 13.46M
- Jan 12, 2024: Shares held short 13.71M
- Jan 31, 2024: Shares held short 12.92M
- Feb 15, 2024: Shares held short 12.02M
- Feb 29, 2024: Shares held short 12.28M
- Mar 15, 2024: Shares held short 11.14M
- Mar 28, 2024: Shares held short 9.52M
- Apr 15, 2024: Shares held short 11.15M
- Apr 30, 2024: Shares held short 12.11M
- May 15, 2024: Shares held short 12.17M
- May 31, 2024: Shares held short 12.31M
- Jun 14, 2024: Shares held short 12.67M
- Jun 28, 2024: Shares held short 16.83M
- Jul 15, 2024: Shares held short 15.10M
- Jul 31, 2024: Shares held short 16.86M
- Aug 15, 2024: Shares held short 17.70M
- Aug 30, 2024: Shares held short 17.14M
- Sep 13, 2024: Shares held short 15.91M
- Sep 30, 2024: Shares held short 14.48M
- Oct 15, 2024: Shares held short 14.39M
- Oct 31, 2024: Shares held short 13.28M
- Nov 15, 2024: Shares held short 16.99M
- Nov 29, 2024: Shares held short 18.07M
- Dec 13, 2024: Shares held short 18.30M
- Dec 31, 2024: Shares held short 19.47M
- Jan 15, 2025: Shares held short 20.20M
- Jan 31, 2025: Shares held short 23.93M
- Feb 14, 2025: Shares held short 25.11M
- Feb 28, 2025: Shares held short 23.91M
- Mar 14, 2025: Shares held short 24.21M
- Mar 31, 2025: Shares held short 25.62M
- Apr 15, 2025: Shares held short 25.46M
- Apr 30, 2025: Shares held short 26.54M
- May 15, 2025: Shares held short 25.54M
- May 30, 2025: Shares held short 26.71M
- Jun 13, 2025: Shares held short 28.47M
- Jun 30, 2025: Shares held short 28.65M
- Jul 15, 2025: Shares held short 28.60M
- Jul 31, 2025: Shares held short 28.70M
- Aug 15, 2025: Shares held short 27.51M
- Aug 29, 2025: Shares held short 26.68M
- Sep 15, 2025: Shares held short 27.01M
- Sep 30, 2025: Shares held short 27.54M
- Oct 15, 2025: Shares held short 25.45M
- Oct 31, 2025: Shares held short 24.17M
- Nov 14, 2025: Shares held short 24.79M
- Nov 28, 2025: Shares held short 22.99M
- Dec 15, 2025: Shares held short 24.03M
- Dec 31, 2025: Shares held short 24.34M
- Jan 15, 2026: Shares held short 25.13M
- Jan 30, 2026: Shares held short 26.06M
- Feb 13, 2026: Shares held short 26.16M
- Feb 27, 2026: Shares held short 24.32M
- Mar 13, 2026: Shares held short 24.30M
- Mar 31, 2026: Shares held short 24.01M
- Apr 15, 2026: Shares held short 23.11M
- Apr 30, 2026: Shares held short 22.65M
- May 15, 2026: Shares held short 22.28M
- May 29, 2026: Shares held short 22.37M
- Jun 15, 2026: Shares held short 23.32M
- Jun 30, 2026: Shares held short 23.51M
- Jul 15, 2026: Shares held short 23.16M
- Jul 31, 2026: Shares held short 22.54M
- Aug 14, 2026: Shares held short 22.29M
- Aug 31, 2026: Shares held short 22.19M
- Sep 15, 2026: Shares held short 22.58M
- Sep 30, 2026: Shares held short 25.92M
- Oct 15, 2026: Shares held short 25.54M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading43.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 43.5% of the shares in the reported trades were short sales, against 44.9% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 43.5%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 44.9%
- Change
- -1.4 pts
- Short sales a dayon average, of 1.82M shares
- 794.1K
- More than atof 3,666 US-listed companies, same days
- 28%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 30.7%
- Oct 15, 2026: Short sales 41%
- Oct 16, 2026: Short sales 36.6%
- Oct 19, 2026: Short sales 54.6%
- Oct 20, 2026: Short sales 51.7%
- Oct 21, 2026: Short sales 44%
- Oct 22, 2026: Short sales 54.1%
- Oct 23, 2026: Short sales 54.9%
- Oct 26, 2026: Short sales 43.7%
- Oct 27, 2026: Short sales 44.5%
- Oct 28, 2026: Short sales 51.2%
- Oct 29, 2026: Short sales 47.8%
- Oct 30, 2026: Short sales 38.6%
- Nov 2, 2026: Short sales 51.8%
- Nov 3, 2026: Short sales 31.2%
- Nov 4, 2026: Short sales 38.7%
- Nov 5, 2026: Short sales 38.8%
- Nov 6, 2026: Short sales 35%
- Nov 9, 2026: Short sales 31.1%
- Nov 10, 2026: Short sales 36.5%
- Nov 11, 2026: Short sales 31.4%
- Nov 12, 2026: Short sales 35.6%
- Nov 13, 2026: Short sales 59.8%
- Nov 16, 2026: Short sales 46.5%
- Nov 17, 2026: Short sales 46.8%
- Nov 18, 2026: Short sales 44.1%
- Nov 19, 2026: Short sales 51.4%
- Nov 20, 2026: Short sales 50.2%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Brian LianPresident & CEODirectly2.57M
- Marianna ManciniChief Operating OfficerDirectly422.8K
- Greg ZanteChief Financial OfficerDirectly212.2K
- Matthew W FoehrDirectorDirectly132.0K
- Lawson MacartneyDirectorDirectly48.0K
- Charles A Rowland JrDirectorDirectly30.0K
- J Matthew SingletonDirectorDirectly9,500
- Dorothy Elizabeth Kelly-GemmellDirectorDirectly6,333
- Neil William AubuchonChief Commercial OfficerDirectly4,475
- Sarah Kathryn RouanDirectorDirectly1,240
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Brian LianPresident & CEO | 2.57M | – | Jul 29, 2026 | Form 4 |
| Marianna ManciniChief Operating Officer | 422.8K | – | Jul 29, 2026 | Form 4 |
| Greg ZanteChief Financial Officer | 212.2K | – | Jul 29, 2026 | Form 4 |
| Matthew W FoehrDirector | 132.0K | – | Jan 2, 2026 | Form 4 |
| Lawson MacartneyDirector | 48.0K | – | Nov 8, 2024 | Form 4 |
| Charles A Rowland JrDirector | 30.0K | – | Oct 27, 2025 | Form 4 |
| J Matthew SingletonDirector | 9,500 | – | Oct 25, 2024 | Form 4 |
| Dorothy Elizabeth Kelly-GemmellDirector | 6,333 | – | Aug 1, 2026 | Form 4 |
| Neil William AubuchonChief Commercial Officer | 4,475 | – | Mar 10, 2026 | Form 4 |
| Sarah Kathryn RouanDirector | 1,240 | – | Mar 31, 2025 | Form 4 |
A lower bound: it counts only the 10 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.30%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.78%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.12%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.08%
- IYHiShares U.S. Healthcare ETFWeight in the fund0.06%
- VXFVanguard Extended Market Index FundWeight in the fund0.05%
- VBVanguard Small-Cap Index FundWeight in the fund0.05%
- VHTVanguard Health Care Index FundWeight in the fund0.05%
- IWSiShares Russell Mid-Cap Value ETFWeight in the fund0.04%
- IWRiShares Russell Mid-Cap ETFWeight in the fund0.03%
28 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 372
- Q4 2025: Managers 427
- Q1 2026: Managers 416
- Q2 2026: Managers 435
Institutional investors by quarter
The fund managers holding VKTX, quarter by quarter, from Q2 2015 to Q2 2025, 41 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 435 managers held 75.77M shares, worth $3.0B. During the quarter 75 opened a position, 56 closed one, 141 added and 127 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter+5.2%
- BlackRockIn the quarter-10%
- State StreetIn the quarter+28%
- Vanguard Capital ManagementIn the quarter+0.8%
- Vanguard Portfolio ManagementIn the quarter+0.4%
- Two Sigma InvestmentsIn the quarter-11%
- Morgan StanleyIn the quarter+16%
- Ameriprise FinancialIn the quarter+28%
- Geode Capital ManagementIn the quarter+0.8%
- American Century CompaniesIn the quarter-13%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 6.34M | +5.2% | $247M |
| BlackRock | 6.19M | -10% | $241M |
| State Street | 5.61M | +28% | $219M |
| Vanguard Capital Management | 5.05M | +0.8% | $197M |
| Vanguard Portfolio Management | 4.48M | +0.4% | $175M |
| Two Sigma Investments | 3.94M | -11% | $154M |
| Morgan Stanley | 3.49M | +16% | $136M |
| Ameriprise Financial | 2.16M | +28% | $84M |
| Geode Capital Management | 2.10M | +0.8% | $82M |
| American Century Companies | 1.82M | -13% | $71M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Viking Therapeutics's filings show?
Who buys and sells is one part of Viking Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have VKTX's insiders bought or sold?
From Jun 3, 2026 to Aug 7, 2026 Viking Therapeutics's insiders bought 0 and sold $6.3M of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold VKTX?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $61M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.